🇪🇺 Flucelvax Trivalent Influenza Vaccine in European Union

EMA authorised Flucelvax Trivalent Influenza Vaccine on 15 November 2024

Marketing authorisation

EMA — authorised 15 November 2024

  • Application: EMEA/H/C/006532
  • Marketing authorisation holder: Seqirus Netherlands B.V.
  • Local brand name: Flucelvax
  • Indication: Prophylaxis of influenza in adults and children from 6 months of age. Flucelvax should be used in accordance with official recommendations.
  • Status: approved

The European Medicines Agency (EMA) has approved Flucelvax Trivalent Influenza Vaccine for the prevention of influenza in adults and children aged 6 months and above. This approval was granted on 15 November 2024, following a standard marketing authorisation application. The vaccine should be used in accordance with official recommendations.

Read official source →

Frequently asked questions

Is Flucelvax Trivalent Influenza Vaccine approved in European Union?

Yes. EMA authorised it on 15 November 2024.

Who is the marketing authorisation holder for Flucelvax Trivalent Influenza Vaccine in European Union?

Seqirus Netherlands B.V. holds the EU marketing authorisation.